Novel binuclear μ-oxo diruthenium complexes combined with ibuprofen and ketoprofen: Interaction with relevant target biomolecules and anti-allergic potential

Synthesis and structural characterization of novel binuclear ruthenium compounds [Ru2O(carb)2(py)6](PF6)2, (py = pyridine; carb = ibuprofen 1 and ketoprofen 2) are reported. Compound 1 is metabolized by the cytochrome P450 enzymes, while compound 2 inhibits mast cell activation, suggesting its promising application as a therapeutic agent for treating or preventing IgE-mediated allergic diseases.157